Agile Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Agile Therapeutics

22/03/2023 21:02

* Agile Therapeutics Inc  AGRX.OQ  reported a quarterly
adjusted
loss of 10 cents​​ per share for the quarter ended in December.
The mean expectation of two analysts for the quarter was for a
loss of 23 cents per share.
    * Revenue rose 163.9% to $4.00 million from a year ago;
analysts
expected $3.09 million. 
    * Agile Therapeutics Inc's reported EPS for the quarter was
a loss
of 10 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Agile Therapeutics Inc shares had risen by 6.3% this
quarter.
    * The company reported a quarterly loss of $3.93 million.
    * Wall Street's median 12-month price target for Agile
Therapeutics Inc is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 22 at 09:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.23          -0.10          Beat
 Sep. 30 2022      -0.44          -0.53          Missed
 Jun. 30 2022      -3.70          -2.71          Beat
                                  -3.78